These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11962518)

  • 1. DNA binding properties of the indolocarbazole antitumor drug NB-506.
    Carrasco C; Vezin H; Wilson WD; Ren J; Chaires JB; Bailly C
    Anticancer Drug Des; 2001; 16(2-3):99-107. PubMed ID: 11962518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
    Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
    Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
    Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
    J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A DNA binding indolocarbazole disaccharide derivative remains highly cytotoxic without inhibiting topoisomerase I.
    Qu X; Chaires JB; Ohkubo M; Yoshinari T; Nishimura S; Bailly C
    Anticancer Drug Des; 1999 Oct; 14(5):433-42. PubMed ID: 10766298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
    Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
    Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indolocarbazole glycosides in inactive conformations.
    Facompré M; Carrasco C; Vezin H; Chisholm JD; Yoburn JC; Van Vranken DL; Bailly C
    Chembiochem; 2003 May; 4(5):386-95. PubMed ID: 12740810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents.
    Bailly C; Dassonneville L; Colson P; Houssier C; Fukasawa K; Nishimura S; Yoshinari T
    Cancer Res; 1999 Jun; 59(12):2853-60. PubMed ID: 10383146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calories from carbohydrates: energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition.
    Bailly C; Qu X; Graves DE; Prudhomme M; Chaires JB
    Chem Biol; 1999 May; 6(5):277-86. PubMed ID: 10322124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
    Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
    J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I.
    Yoshinari T; Ohkubo M; Fukasawa K; Egashira S; Hara Y; Matsumoto M; Nakai K; Arakawa H; Morishima H; Nishimura S
    Cancer Res; 1999 Sep; 59(17):4271-5. PubMed ID: 10485471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle.
    Moreau P; Anizon F; Sancelme M; Prudhomme M; Bailly C; Carrasco C; Ollier M; Sevère D; Riou JF; Fabbro D; Meyer T; Aubertin AM
    J Med Chem; 1998 May; 41(10):1631-40. PubMed ID: 9572888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
    Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y
    Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
    Yoshinari T; Matsumoto M; Arakawa H; Okada H; Noguchi K; Suda H; Okura A; Nishimura S
    Cancer Res; 1995 Mar; 55(6):1310-5. PubMed ID: 7882328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue.
    Bailly C; Qu X; Anizon F; Prudhomme M; Riou JF; Chaires JB
    Mol Pharmacol; 1999 Feb; 55(2):377-85. PubMed ID: 9927631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the inverted CCAAT box 2 in the topoisomerase IIalpha promoter by JH-37, an imidazole-pyrrole polyamide hairpin: design, synthesis, molecular biology, and biophysical studies.
    Henry JA; Le NM; Nguyen B; Howard CM; Bailey SL; Horick SM; Buchmueller KL; Kotecha M; Hochhauser D; Hartley JA; Wilson WD; Lee M
    Biochemistry; 2004 Sep; 43(38):12249-57. PubMed ID: 15379563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
    Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
    Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles.
    Facompre M; Carrasco C; Colson P; Houssier C; Chisholm JD; Van Vranken DL; Bailly C
    Mol Pharmacol; 2002 Nov; 62(5):1215-27. PubMed ID: 12391286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, biological evaluation, and molecular modeling studies of rebeccamycin analogues modified in the carbohydrate moiety.
    Animati F; Berettoni M; Bigioni M; Binaschi M; Felicetti P; Gontrani L; Incani O; Madami A; Monteagudo E; Olivieri L; Resta S; Rossi C; Cipollone A
    ChemMedChem; 2008 Feb; 3(2):266-79. PubMed ID: 18157856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, mode of action, and biological activities of rebeccamycin bromo derivatives.
    Moreau P; Anizon F; Sancelme M; Prudhomme M; Sevère D; Riou JF; Goossens JF; Hénichart JP; Bailly C; Labourier E; Tazzi J; Fabbro D; Meyer T; Aubertin AM
    J Med Chem; 1999 May; 42(10):1816-22. PubMed ID: 10346933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromophore-modified bisnaphthalimides: DNA recognition, topoisomerase inhibition, and cytotoxic properties of two mono- and bisfuronaphthalimides.
    Bailly C; Carrasco C; Joubert A; Bal C; Wattez N; Hildebrand MP; Lansiaux A; Colson P; Houssier C; Cacho M; Ramos A; Braña MF
    Biochemistry; 2003 Apr; 42(14):4136-50. PubMed ID: 12680768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.